AstraZeneca reports major survival gains for Tagrisso‑savolitinib combo and Sone‑Ve ADC at ESMO 2026
At the ESMO 2026 meeting AstraZeneca disclosed Phase 3 results for two oncology candidates. The Tagrisso‑savolitinib combination extended median progression‑free survival to 7.5 months (vs 5.4 months with chemotherapy) and added 4.9 months overall survival in MET‑positive, EGFR‑mutant lung cancer, while in first‑line MET‑IHC3+ patients median PFS was 24.5 months (vs 11.3 months) and overall survival reached 44.5 months. The Sone‑Ve antibody‑drug conjugate for advanced gastric cancer cut the risk of death by 53% (hazard ratio 0.47) and raised one‑year survival to 38.1% from 18.1% in the third‑line‑plus setting.
Why it matters
The company cites a $3 billion to $5 billion revenue opportunity for Sone‑Ve, suggesting a potential blockbuster that could materially boost future sales. Management also indicated that additional readouts are expected in 2027, which may further shape the oncology pipeline valuation.
Key facts
- 1Tagrisso‑savolitinib median progression‑free survival was 7.5 months versus 5.4 months for chemotherapy. finance.yahoo.com
- 2The combination added a 4.9‑month overall survival improvement versus standard chemotherapy. finance.yahoo.com
- 3In MET IHC 3+ first‑line patients, median progression‑free survival was 24.5 months versus 11.3 months for chemotherapy. finance.yahoo.com
- 4Overall survival in that first‑line cohort was 44.5 months. finance.yahoo.com
- 5Sone‑Ve reduced the risk of death by 53% (hazard ratio 0.47) in third‑line‑plus gastric cancer patients. finance.yahoo.com
- 6One‑year survival was 38.1% for Sone‑Ve versus 18.1% for the control arm. finance.yahoo.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.